Catalyst Pharma Group

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases. The company's lead product, Firdapse (amifampridine), is the first and only FDA-approved treatment for Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also markets Agamree (vamorolone), a dissociative steroid for Duchenne Muscular Dystrophy, and Fycompa (perampanel) for the treatment of epilepsy. The company is actively expanding its portfolio through strategic acquisitions and lifecycle management of its existing assets. Catalyst is headquartered in Coral Gables, Florida, and is publicly traded on the NASDAQ under the symbol CPRX.